Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 63; no. 3; p. 367
• Main Authors: Baker, Jason V, Huppler Hullsiek, Katherine, Bradford, Robert L, Prosser, Rachel, Tracy, Russell P, Key, Nigel S
• Format: Journal Article
• Language: English
• Published: United States 01.07.2013
• Subjects: Adult; Anti-HIV Agents - therapeutic use; Blood Coagulation - drug effects; Blood Coagulation Tests; C-Reactive Protein - analysis; Cell-Derived Microparticles; Female; HIV Infections - blood; HIV Infections - drug therapy; Humans; Inflammation - immunology; Interleukin-6 - blood; Male; Middle Aged; Thromboplastin - analysis; Thromboplastin - metabolism; von Willebrand Factor - analysis
• ISSN: 1944-7884
• DOI: 10.1097/QAI.0b013e3182910121

Activation of coagulation pathways may contribute to risk for non-AIDS-related conditions among HIV-positive patients. Tissue factor (TF)-dependent procoagulant activity on circulating microparticles (MP-TF) in the plasma of 163 HIV-positive participants, both untreated and treated, with viral suppression was measured. MP-TF activity was 39% lower among treated versus untreated participants (P < 0.001), which persisted in adjusted models (-36%, P = 0.03). Among treated participants, MP-TF activity correlated modestly with D-dimer (r = 0.24, P = 0.01), von Willebrand factor (r = 0.36, P < 0.001), and interleukin-6 (r = 0.20, P = 0.04) levels. Future research should focus on mechanisms driving residual functional TF activity and whether these alterations have clinical consequences for non-AIDS-defining complications.